Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Opin Investig Drugs. 2009 Apr;18(4):541-8. doi: 10.1517/13543780902845622 .

Copper chelation in cancer therapy using tetrathiomolybdate: an evolving paradigm.

Author information

1
University of Michigan, Ann Arbor, MI, USA. gkhan@umich.edu

Abstract

BACKGROUND:

Tetrathiomolybdate (TM) is a novel anticancer and anti-angiogenic agent, which acts through copper chelation and NF-kappaB inhibition.

OBJECTIVE:

This review summarizes the scientific rationale for the use of TM as an anticancer agent in human studies.

METHODS:

A systematic review of the literature was conducted for the use of TM in cancer including preclinical, animal and human studies. The results of this search are summarized in this review.

RESULTS/CONCLUSIONS:

Copper chelation using TM has demonstrated efficacy in preclinical and animal models as an alternative and novel anti-angiogenic agent. Phase I and II clinical trials conducted in solid tumors using TM have demonstrated efficacy with favorable toxicity profile. The use of copper lowering as an anti-angiogenic strategy in the cancer chemopreventative setting remains to be investigated.

PMID:
19335282
DOI:
10.1517/13543780902845622
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center